Trial Profile
A Phase 1, Randomized, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Single Oral Doses of JTT-252 in Healthy Subjects (Part I); in Conjunction With an Open-label Study to Evaluate the Effect of Food on the PK of JTT-252 in Healthy Subjects (Part II); and an Open-label Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics (PD) of Single Oral Doses of JTT-252 in Type 2 Diabetic Subjects (Part III)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 May 2015
Price :
$35
*
At a glance
- Drugs JTT 252 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Akros Pharma
- 30 Apr 2015 Status changed from recruiting to discontinued as reported by ClincialTrials.gov.
- 09 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClincialTrials.gov record.
- 09 Feb 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClincialTrials.gov record.